AgomAb Therapeutics NV Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, AgomAb Therapeutics NV stock has a consensus rating of "Strong Buy" and an average price target of $37.67. The average 1-year stock price forecast is 209.53% higher than the current stock price, while the lowest is $28 (+130.07%) and the highest is $60 (+393.02%).

Price Target: $37.67 (+209.53%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$28	$37.67	$34.5	$60
Change	+130.07%	+209.53%	+183.48%	+393.02%

Analyst Ratings

The average analyst rating for AgomAb Therapeutics NV stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	1	1	2	3	4	4
Buy	2	2	2	2	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	4	5	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anupam Rama J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Sep 15, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $60	Buy	Maintains	$60	+393.02%	Sep 15, 2026
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $35	Buy	Reiterates	$35	+187.59%	Sep 15, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $28	Buy	Maintains	$28	+130.07%	Sep 8, 2026
Yanni Souroutzidis Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates $13 → $17	Buy	Initiates	$13 → $17	+39.69%	Aug 19, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.61

from -146.03

EPS Next Year

-1.80

from -1.61

Fiscal Year	FY 2019	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2019	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-3.09M	-22.63M	-31.19M	-48.02M	-59.28M	-78.55M
Net Income	-3.05M	-8.14M	-11.39M	-46.27M	-62.55M	-71.59M
EPS	-	-	-	-	-146.03	-1.61
Free Cash Flow	-	-	-	-	-51.75M	-72.90M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.41
Avg	-1.61
Low	-1.81

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-